UK Markets close in 7 hrs 18 mins

Global Anaplastic Lymphoma Kinase (ALK) Inhibitors Market 2020-2024: Focus on First, Second & Third Generation ALK Inhibitors - ResearchAndMarkets.com

·3-min read

The "Global Anaplastic Lymphoma Kinase (ALK) Inhibitors Market 2020-2024" report has been added to ResearchAndMarkets.com's offering.

The anaplastic lymphoma kinase (ALK) inhibitors market is poised to grow by $2.96 bn during 2020-2024 progressing at a CAGR of 20% during the forecast period.

The reports on anaplastic lymphoma kinase (ALK) inhibitors market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the high target affinity and specificity of ALK inhibitors and high prevalence of lung cancer. In addition, high target affinity and specificity of ALK inhibitors is anticipated to boost the growth of the market as well.

This study identifies by the presence of patient assistance programs as one of the prime reasons driving the anaplastic lymphoma kinase (ALK) inhibitors market growth during the next few years. The author presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters.

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading anaplastic lymphoma kinase (ALK) inhibitors market vendors that include AstraZeneca Plc, Betta Pharmaceuticals Co. Ltd., Bio-Techne Corp., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Merck KGaA, Novartis AG, Pfizer Inc., Takeda Pharmaceutical Co. Ltd., and Turning Point Therapeutics Inc..

Also, the anaplastic lymphoma kinase (ALK) inhibitors market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Key Topics Covered:

Executive Summary

  • Market Overview

Market Landscape

  • Market ecosystem

  • Value chain analysis

Market Sizing

  • Market definition

  • Market segment analysis

  • Market size 2019

  • Market outlook: Forecast for 2019 - 2024

Five Forces Analysis

  • Five forces summary

  • Bargaining power of buyers

  • Bargaining power of suppliers

  • Threat of new entrants

  • Threat of substitutes

  • Threat of rivalry

  • Market condition

Market Segmentation by Type

  • Market segments

  • Comparison by Type

  • Second-generation ALK inhibitors - Market size and forecast 2019-2024

  • First-generation ALK inhibitors - Market size and forecast 2019-2024

  • Third-generation ALK inhibitors - Market size and forecast 2019-2024

  • Market opportunity by Type

Customer landscape

Geographic Landscape

  • Geographic segmentation

  • Geographic comparison

  • North America - Market size and forecast 2019-2024

  • Europe - Market size and forecast 2019-2024

  • Asia - Market size and forecast 2019-2024

  • ROW - Market size and forecast 2019-2024

  • Key leading countries

  • Market opportunity by geography

  • Volume drivers - Demand led growth

  • Volume drivers - External factors

  • Market challenges

  • Market trends

Vendor Landscape

  • Overview

  • Vendor landscape

  • Landscape disruption

Vendor Analysis

  • Vendors covered

  • Market positioning of vendors

  • AstraZeneca Plc

  • Betta Pharmaceuticals Co. Ltd.

  • Bio-Techne Corp.

  • F. Hoffmann-La Roche Ltd.

  • GlaxoSmithKline Plc

  • Merck KGaA

  • Novartis AG

  • Pfizer Inc.

  • Takeda Pharmaceutical Co. Ltd.

  • Turning Point Therapeutics Inc.

Appendix

For more information about this report visit https://www.researchandmarkets.com/r/9rtdm4

View source version on businesswire.com: https://www.businesswire.com/news/home/20201030005484/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900